Dysregulation of TAp63 mRNA and protein levels in psoriasis

Journal of Investigative Dermatology

Volumn 126, Issue 1, 2006, Pages 137-141

  Gu, Xiaolian ^a   Lundqvist, Elisabet N ^b   Coates, Philip J ^c   Thurfjell, Niklas ^a   Wettersand, Emma ^a   Nylander, Karin ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53; PROTEIN P63; PROTEIN TAP63; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PSORIASIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SKIN; TRANSCRIPTION REGULATION;

ADULT; AGED; DNA-BINDING PROTEINS; DOWN-REGULATION; EPIDERMIS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PSORIASIS; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33644756625     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700010     Document Type: Article

References (28)

1. Bamberger C, Hafner A, Schmale H, Werner S (2005) Expression of different p63 variants in healing skin wounds suggests a role of p63 in reepithelialization and muscle repair. Wound Repair Regen 13:41-50
2. Bamberger C, Pollet D, Schmale H (2002) Retinoic acid inhibits downregulation of DeltaNp63alpha expression during terminal differentiation of human primary keratinocytes. J Invest Dermatol 118:133-8
3. De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A et al. (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 273:342-6
4. Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE (2005) Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 124:373-83
5. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L (2002) Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 22:8659-68
6. Ghioni P, D'Alessandra Y, Mansueto G, Jaffray E, Hay RT, Mantia GL (2005) The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4:183-90
7. Gottlieb AB (2005) Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4:19-34
8. Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y (2000) p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 19:3126-30
9. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18:126-31
10. Koster MI, Roop DR (2004) The role of p63 in development and differentiation of the epidermis. J Dermatol Sci 34:3-9
11. Lin J, Jin X, Rothman K, Lin HJ, Tang H, Burke W (2002) Modulation of signal transducer and activator of transcription 3 by p53 tumor suppressor in breast cancer cells. Cancer Res 62:376-80
12. McKenzie RC, Sabin E (2003) Aberrant signaling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp Dermatol 12:337-45
13. Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664-75
14. Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Matsumura Y et al. (2001 ) p53 homologue p63 represses epidermal growth factor receptor expression. J Biol Chem 276:41717-24
15. Nylander K, Coates PJ, Hall PA (2000) Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 87:368-72
16. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos C, Zhanxiang W et al. (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198:417-27
17. Nylander Lundqvist E, Egelrud T (1997) Biologically active, alternatively processed interleukin-1 beta in psoriatic scales. Eur J Immunol 27:2165-71
18. Okada Y, Osada M, Kurata S, Sato S, Aisaki K, Kageyama Y et al. (2002) p53 gene family p51 (p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res 276:194-200
19. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I et al. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4:839-43
20. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K et al. (2005) Sta3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11:43-9
21. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C et al. (2002) The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 277:719-24
22. Shen CS, Tsuda T, Fushiki S, Mizutani H, Yamanishi K (2005) The expression of p63 during epidermal remodeling in psoriasis. J Dermatol 32:236-42
23. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K et al. (1999) The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59:2781-6
24. Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A et al. (2004) Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 25:27-35
25. Westfall MD, Pietenpol JA (2004) p63: molecular complexity in development and cancer. Carcinogenesis 25:857-64
26. Yang A, Kaghad M, Wang Y, Gillett A, Fleming MD, Dotsch V et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-16
27. Ying H, Chang DL, Zheng H, McKeon F, Xiao ZX (2005) DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol 25:6154-64
28. Yu H, Jove R (2004) The stats of cancer - new molecular targets come of age. Nat Rev Cancer 4:97-105